Table 4 Correlations between the USP3 and EPHA2 expression levels and clinical characteristics.

From: USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/AKT signaling pathway

Characteristics

Total (n = 34)

USP3

P value

EPHA2

P value

Low

High

Low

High

Age (year)

   

0.141

  

0.724

 <18

21

6

15

 

10

11

 

 ≥18

13

7

6

 

7

6

 

Gender

   

0.183

  

0.716

 Male

16

8

8

 

7

9

 

 Female

18

5

13

 

9

9

 

Metastasis

   

0.001

  

0.039

 Positive

17

11

6

 

11

6

 

 Negative

17

2

15

 

5

12

 

Tumor size (cm3)

   

0.092

  

0.595

 <10

10

6

4

 

4

6

 

 ≥10

24

7

17

 

12

12

 

Clinical stage

   

0.042

  

0.017

 I&II

16

9

7

 

11

5

 

 III&IV

18

4

14

 

5

13

 

Tumor site

   

0.961

  

0.153

 Limb

26

10

16

 

14

12

 

 Other

8

3

5

 

2

6

 
Back to article page